Cytek Biosciences enters the week after Q1 results fighting a 15% price drop, fresh target cuts from two analysts, and a short base that remains stubbornly elevated.
The stock closed at $4.04 on Tuesday, down from $4.78 a week earlier. The selloff follows last Wednesday's Q1 earnings report, which prompted a 6.7% one-day decline. Despite beating revenue estimates and reaffirming full-year guidance of $205M–$212M, an EPS miss was enough to push the stock to its lowest level in recent months. The week's -15.5% move stands in stark contrast to peers — BRKR gained 18% over the same period, and RVTY added 7.6%, highlighting how company-specific the pressure on CTKB has been.
The response from the Street has been swift, if not dramatic. Morgan Stanley lowered its price target from $6.00 to $5.50 yesterday, maintaining its Equal-Weight rating — a posture that reads as "fair value, but no catalyst here." Stephens & Co. followed today, trimming its target from $5.50 to $4.75 while keeping its Overweight rating intact. The mean target across the analyst base now sits at $6.00, still almost 50% above the current price. That gap deserves a measure of caution: Goldman Sachs has held a Sell rating on the stock for some time, and the direction of target revisions has been consistently downward for well over a year. Valuation multiples tell a mixed story — the EV/EBITDA ratio fell sharply over the past 30 days, dropping 35 points to around 51x, while the price-to-book ratio has compressed to 1.5x.
The positioning picture reflects a stock under modest but real pressure from short sellers. Short interest runs at 6.1% of the free float — meaningful, though not extreme. The short base peaked earlier in May above 8.1 million shares and has pulled back roughly 4% on the week to 7.8 million shares. Borrowing costs have eased alongside that retreat, falling 17% over the past month to 0.51% — near the lowest level in the 30-day window. Availability in the lending market remains very loose, consistent with a borrow environment that poses no squeeze risk to anyone holding short positions. The ORTEX short score of 56, in the 26th percentile relative to the broader universe, reflects a stock where shorts are present but not pushing hard. Options are similarly relaxed — the put/call ratio of 0.30 runs slightly above its 20-day average of 0.24 but carries a z-score of just 0.6, far from any defensively charged reading. There is no particular options asymmetry here.
The EPS momentum picture is the sharpest red flag. Both the 30-day and 90-day EPS momentum factor scores rank in the 1st percentile — estimates have been cut hard and cut repeatedly. That sits alongside an EPS surprise score of 89, which captures a longer track record of beating lowered bars. The dynamic is a familiar one in life sciences tools: guidance holds, but the cadence of estimate reductions erodes sentiment. Factor scores for days-to-cover and short score rank are both below the 30th percentile, reinforcing the view that this is not a heavily squeezed name but one where the fundamental narrative is doing most of the work on the downside.
Institutional ownership adds one notable data point. Millennium Management added 1.9 million shares in its most recently reported period, becoming the largest disclosed institutional holder at 5.1% of shares. That's a meaningful build from a quantitative hedge fund and worth tracking alongside the next filing window.
The next scheduled earnings event is June 10. With two target cuts already in the bag following Q1 and EPS momentum at the floor of the universe, the June print will be watched closely for any sign that the guidance range is holding — or narrowing.
See the live data behind this article on ORTEX.
Open CTKB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
